Determining the functions of post-translational modifications (PTMs)[^1^](#G1){ref-type="fn"} is a grand challenge in post-genomic biology. Locating modified sites is often an essential first step toward ascertaining the biological roles of PTMs, and liquid chromatography coupled to tandem mass spectrometry (LC-MS/MS) has emerged as a choice technology for this purpose. For example, LC-MS/MS has been successfully utilized in recent proteomic surveys of phosphorylation ([@B1], [@B2]), acetylation ([@B3], [@B4]), ubiquitination ([@B5], [@B6]), and glycosylation ([@B7][@B8][@B9]--[@B10]) sites. Modifications such as these can profoundly impact the molecular biology of a protein. Unambiguous assignment of PTM locations using existing LC-MS/MS methodology is sometimes difficult to achieve, particularly in cases involving low protein abundance or low site occupancy. Adding to the technical challenge of site mapping, PTMs such as glycosylation are known to reduce ionization efficiency and, therefore, detectability via MS ([@B11][@B12]--[@B13]). In highly complex proteomic samples, low intensity ions generated from glycopeptides may be overlooked because of instrument-dependent limitations on the rate at which ions can be selected for fragmentation during data-dependent acquisition ([@B14]). Here, we describe a targeted proteomic approach, in which LC-MS/MS analysis is focused specifically on peptides bearing *N*-glycosylation, a common PTM found in all major phylogenetic branches of life. In contrast to data-dependent methods that select a subset of relatively intense ions for fragmentation, our approach is specifically designed to provide intensity-independent fragmentation priority to peptides most likely to bear *N*-glycans and boost confidence in correct PTM site assignment.

In eukaryotes, *N*-glycosylation is a PTM frequently found on proteins that are translated into the endoplasmic reticulum (ER). Structurally conserved *N*-glycan precursors are synthesized via the dolichol pathway and transferred onto nascent proteins; the glycosylated Asn residues are typically found within a subset of the polypeptide N*X*(S/T) motifs, where *X* denotes a non-proline residue ([@B15], [@B16]). Biologically, *N*-glycans contribute to the folding, trafficking, and thermodynamic stability of proteins exposed to ER, vacuolar, and Golgi lumens, as well as those destined for exposure to the extracellular milieu ([@B17]). The *N*-glycan precursors are enzymatically edited to yield a plethora of mature glycoforms with compositions largely dependent on cell type and protein localization. Sometimes, specific *N*-glycan structures are required for protein function, whereas in other cases, *N*-glycans primarily contribute to protein stability and solubility ([@B18]). As a class, the *N*-glycosylation modification is biologically essential; chemical or genetic disruption of *N*-glycan biosynthesis is lethal, and aberrant *N*-glycosylation is associated with several human disease states ([@B19], [@B20]).

Many existing LC-MS/MS approaches for mapping *N*-glycosites depend on enzymatic removal of the entire *N*-glycan following stringent sample enrichment to remove nonglycosylated peptides prior to analysis ([@B9], [@B10]). These methods rely on detection of a 0.98-Da mass increase resulting from the enzymatic deamination of glycosylated Asn residues by peptide:*N*-glycosidase F (PNGase F). Enzymatic deamination is often performed in the presence of ^18^O-labeled water, imparting a 2.98-Da mass shift to the peptide to increase confidence in site assignment ([@B7]). Unfortunately, complete removal of *N*-glycans with PNGase F can lead to instances of incorrectly mapped glycosites. During the course of PNGase F treatment, spontaneous deamination of nonglycosylated Asn residues and other instances of PNGase F-independent incorporation of ^18^O can potentially yield false positives ([@B21][@B22]--[@B23]). This drawback has led to the development of alternative strategies utilizing partial rather than total removal of *N*-glycans; for instance, treating samples with the enzyme endoglycosidase H preserves a single core GlcNAc residue, leaving direct evidence for *N*-glycosylation intact ([@B23], [@B24]). Unfortunately, the presence of even a single sugar residue on peptides is known to considerably suppress ionization efficiency ([@B8], [@B13]), potentially biasing data-dependent LC-MS/MS data acquisition against glycopeptide ions. Despite this limitation, detection of the retained glycan by LC-MS/MS provides unequivocal evidence for glycosite assignment instead of indirect evidence that the *N*-glycan modification once existed at a given site. Therefore, LC-MS/MS methods that could select low abundance ions for fragmentation could greatly benefit glycosite mapping.

Recently, we described a strategy for addressing the challenge of identifying low abundance species in complex mixtures based on a directed LC-MS/MS approach ([@B25]). Termed isotopic signature transfer and mass pattern prediction (IsoStamp), the technique exploits the perturbing effects of a dibrominated chemical tag on the isotopic envelope of a peptide. Once covalently modified with the tag, dibrominated peptides can be readily detected with high sensitivity and fidelity in high resolution LC-MS data using a novel computational pattern-searching algorithm. Pattern identification allows targeted proteomic analyses of labeled peptides in complex biological samples; inclusion lists containing *m*/*z* values and retention times of ions bearing recoded envelopes are used to trigger fragmentation. Thus, isotopic pattern rather than ion abundance is used to drive this directed proteomic approach. The IsoStamp method was an extension of the concept of isotopic distribution encoding tagging reported by Goodlett *et al.* ([@B26]).

Although the isotopic signature of a halogenated tag can effectively highlight labeled peptides within a complex LC-MS data set, its utility is restricted to those situations in which the desired subset of peptides can be chemospecifically modified. Here, we demonstrate that it is possible to impart a similar perturbation to the isotopic envelope of a peptide without the requirement for chemical tagging. Instead, our approach metabolically embeds a dibromide-like isotopic signature directly into glycans. In this study, we mimic the dibromide isotopic signature with a stoichiometrically defined mixture of GlcNAc isotopologs, referred to as a GlcNAc isomix. The isomix is metabolically installed into structurally conserved *N*-glycan core positions, marking them with a uniquely identifiable isotopic signature. We employed the technique to map occupied *N*-glycosites on proteins from whole *Saccharomyces cerevisiae* lysates. Via preferential fragmentation of isotopically recoded glycopeptides, we identified numerous *N*-glycosites within the yeast proteome, nearly doubling the number that was previously known. The isomix method offers an enhanced level of confidence for mapping glycosylation sites that was not previously available to LC-MS/MS analyses because of the unique isotopic envelope of an isomix-containing peptide. Here, we showcase the utility of isotopic recoding by surveying metabolically labeled *N*-glycans in yeast, but we believe the technology is extendable to other PTMs and organisms through a variety of labeling strategies.

EXPERIMENTAL PROCEDURES
=======================

### 

#### Synthesis of GlcNAc Isotopologs

The synthesis of *N*-acetyl-[d]{.smallcaps}-glucosamine from [d]{.smallcaps}-glucosamine hydrochloride was performed in a single synthetic step as previously described ([@B27]). To a solution of the [d]{.smallcaps}-glucosamine hydrochloride salt (150 mg, 0.6 mmol) in water was added Dowex 200--400 mesh (OH^−^) anion exchange resin, and the pH was adjusted to 7.5. The resin was removed by filtration, yielding a [d]{.smallcaps}-glucosamine solution in 6 ml of water. To this solution was added \[^13^C~2~\]sodium acetate (1.1 eq, Cambridge Isotope Laboratories) as a predissolved solution in water and 2-ethoxy-1-ethoxycarbonyl-1,2-dihydroquinoline (1.1 eq) as a predissolved solution in 10 ml of ethanol. The total reaction volume was brought to 40 ml by the addition of ethanol. The reaction was covered in foil and stirred for 36 h at room temperature. This reaction was repeated using 1-\[^13^C,^15^N\][d]{.smallcaps}-glucosamine hydrochloride (Isotec) as the starting material. After ethanol evaporation under reduced pressure, the crude products were purified by silica gel chromatography using a 10:4:3 mixture of ethyl acetate:pyridine:water, dried, filtered, lyophilized, and stored at −20 °C.

#### Preparation of GlcNAc Isomix

Stock solutions of 10 m[m]{.smallcaps} *N*-acetyl-[d]{.smallcaps}-glucosamine, *N*-\[1,2-^13^C~2~\]acetyl-[d]{.smallcaps}-glucosamine, and *N*-\[1,2-^13^C~2~\]acetyl-[d]{.smallcaps}-\[1-^13^C;^15^N\]glucosamine in water were prepared. The solutions were combined to produce a mixture of the GlcNAc isotopologs at a 1:2:1 molar ratio, respectively. The mixture was analyzed by direct infusion on a Thermo-Finnigan LTQ-XL mass spectrometer set to zoom scan, with the signal averaged over 20 scans. The isotopic ratios were then adjusted by the iterative addition of the desired isotopes until a nearly perfect 1:2:1 peak intensity ratio was observed empirically (see [Fig. 1](#F1){ref-type="fig"}*b*). The isomix sample was lyophilized and stored at −20 °C.

#### Cell Culture and Sample Preparation

Detailed descriptions of cell culture conditions and sample preparation are included in the [supplemental information](http://www.mcponline.org/cgi/content/full/M111.015339/DC1). Briefly, lysates from log phase and stationary phase GlcNAc isomix-supplemented yeast cultures were prepared for MS analysis via a modified version of the previously described filter-aided sample preparation methodology ([@B10], [@B28]).

#### Mass Spectrometric Analysis

Prior to analysis, the samples were resuspended in 50 μl of water, and 2.5--5 μl aliquots were subjected to reverse phase liquid chromatography with an Agilent 1200 LC system connected in-line to a LTQ Orbitrap XL hybrid mass spectrometer. External mass calibration was performed prior to analysis. A binary solvent system consisting of buffer A (0.1% formic acid in water (v/v)) and buffer B (0.1% formic acid in acetonitrile (v/v)) was employed. The mass spectrometer was outfitted with a nanospray ionization source. The LC was performed using a 100-μm fritted capillary (New Objective) precolumn self-packed with 1 cm of 5 μm, 200 Å Magic C18AQ resin (Michrom Bioresources) followed by a 100-μm fused silica capillary (Polymicro Technologies) self-packed with 15 cm of 5 μm, 100 Å Magic C18AQ resin (Michrom Bioresources). After sample injection and a 20 min loading step in 2% buffer B, peptides were eluted using a gradient from 7% to 35% buffer B over 150 min, followed by a washing step in 99% buffer B for 20 min. A solvent split was used to maintain a flow rate of 400 nl min^−1^ at the column tip.

The samples were subjected to an inclusion list-driven targeted acquisition method. First, we collected only full scan mass spectra in positive ion mode over the *m*/*z* scan range of 400--1,700 or 400--1,800 using the Orbitrap mass analyzer in profile mode at a resolution of 60,000 (at 400 *m*/*z*). Noise reduction and peak detection were performed using software developed in-house making use of a continuous wavelet transform ([@B25], [@B29]). The centroided mzXML files were then pattern searched for recoded envelopes ([@B25]). The output was an inclusion list that contained the *m*/*z* value (M+2 ion in the isotopic envelope of the labeled peptide) and a retention time window (± 1.5 min, empirically determined) for each labeled peptide. The same sample, stored at 4 °C, was then reanalyzed with identical chromatographic conditions using an inclusion list-driven selection of precursor ions for fragmentation. In relatively rare instances we observed a chromatographic anomaly causing substantially shifted peptide elution profiles; in these cases the experiment was repeated. For each full scan mass spectrum, up to eight CID fragmentation events were performed in the linear ion trap. Dynamic exclusion and charge state screening were enabled to reject ions with an unknown or +1 charge state. An isolation window (IW) of 2 or 4 Da, a minimum threshold of 500 ion counts, and activation energy of 35 were used when triggering a fragmentation event.

#### Database Searches

Peptide identities were obtained using the SEQUEST search algorithm ([@B30]) within Proteome Discoverer 1.2 (Thermo-Fisher). CID spectra were searched against the sequence database generated from all systematically named *S. cerevisiae* ORFs (downloaded March 2011) ([@B31]) augmented with sequences from the common repository of adventitious proteins (cRAP, from the Global Proteome Machine Organization, downloaded March 2011) and the Ngt1 (*C. albicans*) and NAGK (*H. sapiens*) protein sequences, totaling 6,739 entries. Indexed databases for tryptic and chymotryptic digests were created allowing for two missed cleavages, one nonenzymatic terminus, one fixed modification (cysteine carboxyamidomethylation, +57.021 Da) and the following variable modifications: methionine oxidation (+15.995 Da) and asparagine GlcNAcylation (only the M + 2 isotopolog, +205.086 Da). Precursor ion tolerance was set to 10 ppm, and the CID fragment tolerance was set to 0.8 Da. The criteria used for filtering search results included using SEQUEST score function (*XCorr*) cutoffs assigned by a 5% maximum false discovery rate obtained from decoy database searches (using reversed sequences from each of the 6,739 entries in our database), an 8-ppm maximum allowed precursor ion mass deviation, and a 40-amino acid maximum allowed peptide length. Approximately 70% of the peptides reported here were identified within a 1% maximum false discovery rate. Importantly, all of the precursor ion and fragmentation spectra were visually inspected for the isomix signature by authors M. A. B. and K. K. P.; only peptides agreed upon by both authors were considered valid identifications. Precursor ion isomix signatures were also visually verified in the corresponding full scan data sets. In cases where the isomix signature was identifiable in the low resolution fragmentation spectra, this additional information was used to verify correct glycosite assignment, especially in peptides containing multiple Asn residues. For data sets collected with an IW of 2, we used the full scan only data set (*i.e.* the LC-MS run, which was subjected to pattern searching) to confirm the isomix signature. In cases where multiple peptide sequences covered a single glycosite, a representative peptide sequence was selected based on CID spectral quality. Factors such as protein biological function and the presence of a canonical *N*-glycosylation consensus motif (N*X*(S/T)) were not used as criteria for accepting or rejecting peptides. Instances of ambiguous PTM assignment within a peptide were resolved by manual inspection of fragment envelopes as necessary. In one case, highlighted in [supplemental Fig. S4](http://www.mcponline.org/cgi/content/full/M111.015339/DC1), the exact site could not be resolved among two possibilities. The primary data associated with this manuscript may be downloaded from the Tranche repository (<https://proteomecommons.org/tranche/>); hash codes are available in the [supplemental information](http://www.mcponline.org/cgi/content/full/M111.015339/DC1).

RESULTS
=======

### 

#### Metabolic Recoding of N-Glycan Cores

Because of the relative ease with which certain *S. cerev*isiae biosynthetic pathways can be manipulated, we chose to metabolically install an unnatural, dibromide-like isotopic signature into glycans. Universal isotopic recoding of *N*-glycans requires metabolic replacement of a conserved sugar residue found in all such structures with a mixture of isotopologs. All eukaryotic *N*-glycans possess a conserved GlcNAcβ1,4GlcNAc disaccharide at the peptide-proximal position; thus, a GlcNAc isomix can potentially label all *N*-glycans in the glycoproteome of the cell. However, to retain the isotopic ratio during metabolism, the GlcNAc isomix must be converted without isotopic dilution to the key metabolic intermediate uridine diphosphate-GlcNAc (UDP-GlcNAc), the donor nucleotide sugar used in construction of *N*-glycan cores. Specifically, cytosolic UDP-GlcNAc serves as the donor substrate for Alg7 in the biosynthesis of GlcNAc-diphosphodolichol; the GlcNAc residue in this precursor is ultimately covalently linked to Asn in the process of *N*-glycosylation ([@B32]). Thus, control over the uridine diphosphate-GlcNAc (UDP-GlcNAc) pool of a cell is critical for execution of the isomix method. We recently generated a *S. cerevisiae* strain that depends on an engineered salvage pathway for procuring precursors of UDP-GlcNAc ([@B33]). The *gna1*Δ yeast strain lacks the ability to perform *de novo* UDP-GlcNAc biosynthesis and instead generates UDP-GlcNAc exclusively by salvaging GlcNAc added to the culture media. In previous work, we exploited this yeast strain to achieve high efficiency replacement of GlcNAc residues with unnatural GlcNAc analogs, which are alternative substrates for the engineered salvage pathway ([@B33]).

In this work, we supplemented cultured *gna1*Δ yeast with a GlcNAc isomix designed to emulate the isotopic signature of two bromine atoms. As shown in [Fig. 1](#F1){ref-type="fig"}*a*, the dibromide pattern is a symmetrical triplet, with major peaks at *M*, *M* + 2, and *M* + 4 at a relative intensity of 1:2:1, because of the relative abundances of the ^79^Br~2~, ^79^Br^81^Br, and ^81^Br~2~ isotopic pairings. To replicate this pattern, a three-part isomix consisting of *N*-acetyl-[d]{.smallcaps}-glucosamine, *N*-\[1,2-^13^C~2~\]acetyl-[d]{.smallcaps}-glucosamine, and *N*-\[1,2-^13^C~2~\]acetyl-[d]{.smallcaps}-\[1-^13^C;^15^N\]glucosamine, mixed in a 1:2:1 molar ratio ([Fig. 1](#F1){ref-type="fig"}*b*), was prepared and added to the *gna1*Δ yeast culture medium ([Fig. 1](#F1){ref-type="fig"}*c*). The isomix is internalized via the GlcNAc-specific transporter Ngt1 borrowed from *Candida albicans*, and cytosolic GlcNAc is subsequently phosphorylated by the heterologously expressed human kinase NAGK. The resulting GlcNAc-6-phosphate isomix is converted to a UDP-GlcNAc isomix and subsequently installed into *N*-glycan cores by endogenous yeast machinery.

![**Metabolic incorporation of a GlcNAc isomix into yeast *N*-glycans.** *a*, the dibromide triplet pattern, with a 1:2:1 relative peak intensity distribution, results from the natural abundances of ^79^Br and ^81^Br isotope pairings. *b*, a three-component GlcNAc isomix mimics the 1:2:1 peak intensity distribution of dibromide by adjusting the concentration of each synthetically made isotopolog. *c*, the GlcNAc isomix enters the *gna1*Δ yeast hexosamine biosynthetic pathway via a heterologous salvage pathway ([@B33]). The isomix signature is subsequently embedded into UDP-GlcNAc and any glycoconjugates that utilize UDP-GlcNAc in their construction, including the structurally conserved cores of *N*-glycans. Following cell lysis, proteolysis, partial enrichment of *N*-glycopeptides, and partial deglycosylation with endoglycosidase H, the distinctive isotopic signatures of *N*-glycopeptides are detected computationally using pattern-matching software ([@B25]). Masses of putative *N*-glycopeptide ions are granted fragmentation priority in subsequent LC-MS/MS analyses for *N*-glycosite identification. The *N*-glycan precursor illustrated here is composed of two core GlcNAc residues (*blue squares*), nine mannose residues (*green circles*), and three glucose residues (*blue circles*).](zjw0051241220001){#F1}

#### Directed Proteomic Analysis of N-Glycosylated Peptides

Samples for LC-MS/MS analysis were generated from lysates of *gna1*Δ *S. cerevisiae* cultures grown to both mid-log and stationary phases in chemically defined, minimal medium. Tryptic and chymotryptic peptides were prepared from the lysates using a modified version of filter-aided sample preparation ([@B10], [@B28]). During this process, mannose-containing glycopeptides were partially enriched by binding to the lectin concanavalin A, and *N*-glycans were truncated to a single GlcNAc residue with the glycosidase endoglycosidase H. To achieve sufficient resolution for isotopic envelope pattern matching, peptides were analyzed on a Thermo-Finnigan LTQ Orbitrap XL mass spectrometer.

Recoded peptide envelopes bear distinctive peak intensity distributions, as illustrated in the simulated isotopic envelopes shown in [Fig. 2](#F2){ref-type="fig"}*a*. The envelope of an isomix-labeled glycopeptide reflects the peptide\'s intrinsic envelope convolved with that of the GlcNAc isomix. The unique pattern resulting from this convolution serves as the basis for detecting putative glycopeptides in complex samples. Importantly, experimentally observed isomix-containing glycopeptide envelopes, as exemplified in [Fig. 2](#F2){ref-type="fig"}*b*, matched our expectations based on simulations ([Fig. 2](#F2){ref-type="fig"}*a*). This allowed us to computationally search (using the IsoStamp algorithm ([@B25])) for the characteristic isomix signature in yeast peptides subjected to LC-MS analysis. Typically, we detected 4,000--5,000 candidate glycopeptide ions (in charge states z = 1 to z = 5) per sample. However, we did not expect all candidate precursors targeted for fragmentation to yield unique, high confidence glycosites. In some cases, high sample complexity contributed to co-eluting ions of similar masses and identical charge states, generating false positive identifications during the automated pattern search routine ([@B25]). Additionally, the precursor inclusion list inherently contains redundancy. For example, several legitimate, isomix-bearing glycopeptides were observed in multiple charge states between *z* = 1 and *z* = 5. Also, we frequently observed more than one peptide covering the same glycosite. The combination of these factors accounts for the discrepancy between putative glycopeptide precursor ions and the high confidence glycosites we report here. Regardless, the *m*/*z* values and retention times of putative glycopeptide ions bearing the isomix signature were used to construct a time-resolved inclusion list for targeted fragmentation. Notably, even with the inclusion of a lectin-based glycopeptide enrichment step during sample preparation, the overwhelming majority of high intensity ions in our samples appeared to be unglycosylated, as indicated by visual and computational inspection of their isotopic envelopes.

![**The perturbing effect of a GlcNAc isomix on a peptide isotopic envelope.** *a*, simulated isotopic envelopes (*z* = 2) for the GlcNAc isomix (*red trace*), an unlabeled peptide from the glycoprotein Ygp1 (NSSSALNITELY, *blue trace*), and the same peptide labeled with the GlcNAc isomix (*violet trace*). The isotopically recoded peptide has a visually distinctive distribution of peak intensities. *b*, in experimental LC-MS data, the isotopic envelope of the precursor ion corresponding to the NSSSALnITELY glycopeptide is shown (the modified Asn residue is shown in *lowercase*). *Highlighted* in *teal* is the precursor ion that was selected from the inclusion list, and the 4-Da isolation window used for fragmentation is shown in *yellow. c*, the CID fragmentation spectra and the peptide assignment for the 758.87 ion (lowercase *n* refers to the *N*-glycosite). Fragment ions that lack the GlcNAc isomix (such as the *y~4~*^+^ and *b~6~*^+^ fragment ions) have narrow isotopic envelopes, whereas fragments including the GlcNAc isomix (such as the *y~6~*^+^ and *b~8~*^+^ fragment ions) show a perturbed isotopic envelope characteristic of the isomix signature.](zjw0051241220002){#F2}

Our directed proteomics approach (see [supplemental Fig. S1](http://www.mcponline.org/cgi/content/full/M111.015339/DC1)) ([@B25]) required duplicate, back-to-back injections for targeted fragmentation of glycopeptides. The first injection was used exclusively to search for GlcNAc isomix signatures in LC-MS data to identify likely glycopeptide ions and inventory them into an inclusion list. In the subsequent injection, candidate glycopeptide ions were subjected to fragmentation by collision-induced dissociation (CID) ([@B34]) only if the ion abundance exceeded a defined threshold and the ions appeared in the correct retention time window. Importantly, the Asn-GlcNAc linkage is resistant to standard CID conditions used to fragment the peptide backbone ([@B35]).

Ions bearing the isomix signature were subjected to CID fragmentation to determine peptide identity and verify *N*-glycosylation. Ions selected for fragmentation were isolated in either a narrow (2-Da) or broad (4-Da) IW. Although a broad IW covers most peaks in an isomix-labeled glycopeptide envelope ([Fig. 2](#F2){ref-type="fig"}*b*), it has the disadvantage of potentially including unrelated ions in the fragmentation spectrum. Conversely, the use of narrow IWs could yield higher quality fragmentation spectra because fewer unrelated ions will be isolated. However, in practice, the use of a 4-Da IW results in the highest number of MS/MS identifications despite the potential decrease in the precursor ion fraction isolated ([@B36]). Indeed, we observed no detrimental effects on peptide assignments in data sets collected using 4-Da *versus* 2-Da IWs. Instead, the use of a broad IW on ions bearing the isomix signature often provided additional information in the fragmentation spectra that was critical to resolving glycosite positional ambiguity. The broad IW was particularly useful for glycosite assignment in the case of peptides containing more than one Asn residue. As illustrated in [Fig. 2](#F2){ref-type="fig"} (*b* and *c*), when the full isotopic envelope of a candidate glycopeptide was isolated for fragmentation using a broad IW, we preserved the isomix signature in all peptide fragments bearing the GlcNAc isomix modification. In contrast, unglycosylated fragments yielded unperturbed mass envelopes. This information was used to resolve cases of ambiguous glycosite assignments that resulted from automated database search engines. In some cases, doubly glycosylated peptides were observed; the presence of two *N*-glycosites on one peptide introduced a doubly convolved isomix signature, resulting in a widened isotopic envelope with a distinctive "stairstep" pattern in peak intensities ([supplemental Fig. S2](http://www.mcponline.org/cgi/content/full/M111.015339/DC1)).

#### Isomix-directed Fragmentation Allows High Confidence N-Glycosite Identification

The unified list of high confidence *N*-glycosites in the yeast proteome (summarized in [Table I](#TI){ref-type="table"}) reflects a combination of results from multiple experiments, conducted with trypsinized and chymotrypsinized samples obtained from both stationary and mid-log phase cultures. A complete list of the observed tryptic and chymotryptic peptides containing these glycosites and their corresponding statistical indicators of quality are included in [supplemental Table S1](http://www.mcponline.org/cgi/content/full/M111.015339/DC1). We detected a total of 133 *N*-glycosites, 12 of which were previously reported in the Uniprot Knowledgebase ([@B37]). Taken collectively with glycosite information from the Uniprot database, there are now 196 experimentally mapped *N*-glycosites spanning 72 proteins in *S. cerevisiae*; 121 novel sites distributed over 52 proteins are reported here. Importantly, 50% of the proteins in [Table I](#TI){ref-type="table"}, highlighted in bold type, have been biochemically validated as *N*-glycosylated. Proteins were considered biochemically validated if they had previously mapped *N*-glycosites or if there was experimental observation of a gel shift following enzymatic deglycosylation ([@B33], [@B37][@B38]--[@B39]). The high correlation between our proteomic observations and the plethora of biochemical validation data for yeast serves as an excellent indicator that the isomix technique yielded a reliable list of *N*-glycoproteins. Moreover, our results suggest that the *gna1*Δ *S. cerevisiae* likely share similar *N*-glycosite occupancy patterns with the BY4743 strain ([@B40]) from which the *gna1*Δ haploid was derived.

###### Occupied high confidence N-glycosites detected in the S. cerevisiae proteome

Peptides covering these glycosites are detailed in [supplemental Table I](http://www.mcponline.org/cgi/content/full/M111.015339/DC1). Biochemically validated *N*-glycoproteins are highlighted with bold type ([@B33], [@B37][@B38]--[@B39]). Previously mapped *N*-glycosites are underlined ([@B37]).

  Systematic name   Uniprot identification code   Standard name   Occupied *N*-glycosites
  ----------------- ----------------------------- --------------- -------------------------------------------------------------------------------------------
  YBR023C           P29465                        CHS3            Asn-323
  YBR074W           P38244                                        Asn-121
  YBR078W           P38248                        ECM33           Asn-209, 267, 279, 328
  **YBR092C**       **P24031**                    **PHO3**        **Asn-162, 315, 356, 390**[*^a^*](#TFI-1){ref-type="table-fn"}
  YBR093C           P00635                        PHO5            Asn-315, 356[*^a^*](#TFI-1){ref-type="table-fn"}, 390[*^a^*](#TFI-1){ref-type="table-fn"}
  YBR139W           P38109                                        Asn-339
  YBR162C           P38288                        TOS1            Asn-236
  YBR171W           P33754                        SEC66           Asn-12
  YBR229C           P38138                        ROT2            Asn-173, 907
  **YBR286W**       **P37302**                    **APE3**        **Asn-85, 96, 115, 150, 162, 371, 427**
  **YCL043C**       **P17967**                    **PDI1**        **Asn-117, 155, 425**
  YCL045C           P25574                        EMC1            Asn-106, 420
  **YCR011C**       **P25371**                    **ADP1**        **Asn-165**
  YDL095W           P33775                        PMT1            Asn-390
  **YDR055W**       **Q12355**                    **PST1**        **[Asn-210, 242]{.ul}**
  **YDR434W**       **Q04080**                    **GPI17**       **Asn-299**
  **YEL001C**       **P40006**                    **IRC22**       **Asn-93, 121**
  YEL002C           P33767                        WBP1            Asn-60, 332
  YEL040W           P32623                        UTR2            Asn-261
  YEL060C           P09232                        PRB1            Asn-594
  **YFR018C**       **P43599**                                    **Asn-179**
  YGL022W           P39007                        STT3            Asn-539
  YGR014W           P32334                        MSB2            Asn-1088
  YGR189C           P53301                        CRH1            Asn-177, 201
  **YGR282C**       **P15703**                    **BGL2**        **Asn-202**
  **YHR028C**       **P18962**                    **DAP2**        **Asn-63, 139**
  **YHR101C**       **P38813**                    **BIG1**        **Asn-144**
  **YHR188C**       **P38875**                    **GPI16**       **[Asn-184]{.ul}**
  **YHR202W**       **P38887**                                    **Asn-305**
  YIL015W           P12630                        BAR1            Asn-268, 366, 398
  **YJL002C**       **P41543**                    **OST1**        **Asn-99, 400**
  YJL171C           P46992                                        Asn-51, 99, 122, 174, 219, 249, 267, 300
  YJL172W           P27614                        CPS1            Asn-176, 228
  YJL192C           P39543                        SOP4            Asn-35
  YKL039W           P32857                        PTM1            Asn-132
  **YKL046C**       **P36091**                    **DCW1**        **Asn-203, 240**
  YLR066W           Q12133                        SPC3            Asn-173
  **YLR084C**       **Q12465**                    **RAX2**        **Asn-333, 524, 640**
  **YLR413W**       **Q06689**                                    **Asn-194, 299**
  YLR450W           P12684                        HMG2            Asn-150
  YML052W           P54003                        SUR7            Asn-47
  **YML130C**       **Q03103**                    **ERO1**        **Asn-53, 468**
  YMR006C           Q03674                        PLB2            Asn-80, 193, 491
  **YMR008C**       **P39105**                    **PLB1**        **Asn-78, 123, 170, 388, 513, 541**
  **YMR058W**       **P38993**                    **FET3**        **[Asn-244,]{.ul} 265, [292, 359, 381]{.ul}**
  **YMR200W**       **Q03691**                    **ROT1**        **[Asn-139]{.ul}**
  **YMR238W**       **Q05031**                    **DFG5**        **Asn-245**
  **YMR297W**       **P00729**                    **PRC1**        **[Asn-124, 479]{.ul}**
  **YMR307W**       **P22146**                    **GAS1**        **Asn-40, 57, 95, 149, 165, 253, 409**
  **YNL160W**       **P38616**                    **YGP1**        **Asn-58/61, 87, 94, 100, 106, 118, 172, 239, 286**
  **YNL327W**       **P42835**                    **EGT2**        **Asn-103, 161**
  **YNR067C**       **P53753**                    **DSE4**        **Asn-886**
  **YOL011W**       **Q08108**                    **PLB3**        **Asn-56, 82, 547**
  YOL030W           Q08193                        GAS5            Asn-24, 60, 166, 299, 344
  YOL154W           Q12512                        ZPS1            Asn-28, 57, 217
  YOR320C           Q12096                        GNT1            Asn-425
  YPL123C           Q02933                        RNY1            Asn-37
  **YPL154C**       **P07267**                    **PEP4**        **[Asn-144, 345]{.ul}**

^*a*^ Sequence ambiguity between PHO3 and PHO5.

For comparative purposes, we also subjected our samples to traditional intensity-driven data-dependent LC-MS/MS, in which the 10 most intense ions in each full scan mass spectrum were selected for CID fragmentation. Significantly, the intensity-dependent analyses typically identified ∼60% of the glycosites found via isomix-directed fragmentation. For instance, in the case of trypsinized lysate prepared from a stationary phase culture, 52 unique glycosites spanning 25 proteins were identified using directed fragmentation. The same sample, subjected to data-dependent fragmentation, yielded only 30 *N*-glycosites in 16 proteins and contained extensive site overlap with the directed data set. This difference illustrates the advantages of directed, intensity-independent approaches for proteomic analyses. Despite being outperformed by a directed proteomic analysis here, the widely used data-dependent fragmentation approach remains a powerful method, and its performance would undoubtedly benefit from more stringent glycopeptide sample enrichment and improved chromatographic resolution of peptides.

Glycoproteins identified in this study were categorized by the manually curated ontological annotations maintained by the *Saccharomyces* Genome Database ([@B31]). An analysis of cellular localization ([Fig. 3](#F3){ref-type="fig"}*a*) reveals that the majority of the *N*-glycoproteins identified in [Table I](#TI){ref-type="table"} typically reside in the yeast ER, plasma membrane, vacuole, and cell wall. Several proteins localize to substructures within these organelles, especially those involved with cytokinesis and cellular budding. Although many of the identified glycoproteins lack known molecular functions, our list was highly represented by peptidases, glycosidases, and glycosyltransferases ([Fig. 3](#F3){ref-type="fig"}*b*). With respect to biological function, highly represented categories include vacuolar proteases and proteins involved in cell wall construction, reshaping, and maintenance ([Fig. 3](#F3){ref-type="fig"}*c*). Several ER- and Golgi-resident proteins participating in the processes of *N*- and *O*-linked glycosylation were also detected. Overall, the ontological distribution of glycoproteins reported here is consistent with our expectations for *N*-glycoproteins in yeast.

![**Ontological analysis of high confidence *N*-glycoproteins.** *N*-Glycoproteins were categorized according to the manually curated ontological annotations including cellular component (*a*), molecular function (*b*), and biological process (*c*) maintained by the *Saccharomyces* Genome Database ([@B31]).](zjw0051241220003){#F3}

In addition to the ontological consistency for our list of *N*-glycoproteins, we detected no plausible cases in which the *N*-glycan modification was present outside the canonical N*X*(S/T) motif. Although noncanonical *N*-glycosites have been reported in higher eukaryotes ([@B10], [@B41]), it is possible that the acceptor substrate promiscuity of the oligosaccharyl transferase complex, which catalyzes the *N*-glycosylation modification, differs among species. A plot of the relative residue frequencies for the 133 occupied glycosites mapped here reveals a strong, 71% *versus* 29% preference for Thr over Ser within the canonical motif ([Fig. 4](#F4){ref-type="fig"}), consistent with *N*-glycosites mapped in other eukaryotic proteins by nonproteomic methods ([@B42]). Additionally, positions surrounding the motif are dominated by hydroxylated and small hydrophobic residues, consistent with expectations for solvent-exposed, loop regions of proteins. Charged residues, especially aspartate, are present in slightly higher frequency on the C-terminal side of the sequon, but not at the −2 position as observed in the case of bacterial *N*-glycosites ([@B43]). Collectively, these data reveal a typical acceptor substrate sequence for the yeast oligosaccharyl transferase.

![**Relative frequencies of residues surrounding yeast *N*-glycosites.** Sequences of the 133 unique glycosylation sites detected by directed LC-MS/MS are aligned on the modified Asn residue. Relative heights of the surrounding amino acids are adjusted based on the frequencies of their occurrence.](zjw0051241220004){#F4}

DISCUSSION
==========

We have demonstrated that a metabolically embedded isotopic signature, designed to emulate the perturbing effects of a dibrominated chemical tag, can serve as the basis for targeted proteomic analysis of a biologically important class of PTM. This approach has two major benefits. First, the ions selected for fragmentation need not be among the most intense in the sample. Second, recoded envelopes contain easily detectable cues indicating whether or not fragmentation spectra have been correctly assigned to a peptide, a feature that is particularly useful for verifying the site of a PTM. We used the approach of isomix-based targeted proteomics to build a relatively small but high confidence list of *N*-glycosites in yeast.

Systematically mapping *N*-glycosylation sites in *S. cerevisiae* provides a wealth of information pertaining to native glycoprotein structure and topology. It is well known that the mere presence of a standard N*X*(S/T) sequon is not sufficient to guarantee glycan attachment to a nascent polypeptide. A number of extenuating factors, ranging from local protein structure to nutrient availability, ultimately determine which sequons are glycosylated. In the case of soluble proteins, fully or partially occupied glycosites are an excellent indicator of sequon surface accessibility. In the case of integral membrane proteins, occupied glycosites confirm that a given Asn is ER-lumenal upon translation and can be used to confirm or reject integral membrane protein topological predictions. In our data, we detected 25 glycosylated integral membrane proteins, and in all cases the occupied glycosites confirm transmembrane hidden Markov model topology predictions ([@B44]) of lumenal *versus* extracellular domains. Additionally, glycosite mapping is a prerequisite for quantitative, comparative analysis of glycan occupancy. Although we do not attempt to quantify glycan occupancy in this study, a high confidence glycosite map serves as the foundation for investigating how glycosite occupancy changes with cell state and growth conditions; such a study can be conducted using established quantitative MS approaches focused on newly verified glycosites and is a subject of interest for future investigations.

Although LC-MS/MS is currently among the best available methods for mapping PTMs such as glycosylation, obtaining high confidence correlations between fragmentation spectra and peptide sequences is not always simple ([@B45]). The utility of tandem MS analysis is ultimately limited by the quality of fragmentation spectra. Because fragmentation spectra are rarely perfect, statistical methods for increasing confidence in peptide assignment remains an active area in research in the field of proteomics ([@B46][@B47]--[@B48]). Advances in instrumentation available to the proteomics community are also reducing the possibility of incorrect spectral assignment. Next generation hardware designed to allow rapid, sensitive, and highly accurate analyses of both precursor and fragment ion masses will undoubtedly reduce false positives in proteomic hit lists ([@B49]). Complementing high mass accuracy, isotopic recoding of PTMs provides an additional restraint for spectral assignment. As illustrated in [Fig. 2](#F2){ref-type="fig"}, precursor and fragment ions corresponding to recoded peptides bear a unique isotopic signature that could be used as a basis for accepting or rejecting a computationally assigned spectral match. Indeed, several peptides in our data were computationally matched to peptides based on favorable statistical indicators, such as high SEQUEST *XCorr* values, but were ultimately rejected because they lacked the characteristic isomix signature in their isotopic envelopes. As illustrated in [supplemental Fig. S3](http://www.mcponline.org/cgi/content/full/M111.015339/DC1), a peptide isolated for CID fragmentation via data-dependent selection was assigned to a GlcNAc-containing peptide from the cytosolic kinase Akl1 with high confidence. However, manual inspection of the isotopic envelope of the precursor ion revealed no evidence of the isomix signature, casting doubt on the assignment. The lack of a standard N*X*(S/T) sequon in this peptide and the cytosolic location of Akl1 are also consistent with spectral misassignment. Thus, we believe isotopic recoding of PTMs can serve as a valuable tool for rejecting incorrect spectral assignments that would otherwise pass undetected into LC-MS/MS hit lists.

By using isotopically recoded glycans, we successfully placed fragmentation priority on glycopeptide ions regardless of their relative intensities to other ions in the sample. As a result, rigorous sample enrichment for *N*-glycopeptides was not essential using the isomix strategy. Nonetheless, we speculate that imperfect enrichment with ConA allowed for the presence of many high abundance, nonglycopeptides in our sample, suppressing ionization and the successful detection and fragmentation of low abundance and poorly ionizing glycopeptides within the yeast proteome. Isotopic recoding is not intended to replace or eliminate enrichment from proteomics workflows; rather, we believe it has the potential to increase the information obtained from a given sample. We expect that enhanced glycopeptide enrichment strategies in conjunction with cellular fractionation and improved chromatographic resolution of peptides will permit detection of additional glycosites; the *S. cerevisiae* proteome has been reported to contain at least 350 *N*-glycosylated proteins ([@B39]).

The concept of isotopically recoding PTMs for targeted LC-MS/MS analysis can be extended well beyond *N*-glycosite mapping. By utilizing endogenous or engineered salvage pathways, unnatural isotopic signatures could be metabolically installed into a variety of PTMs. The relative malleability of glycan biosynthetic pathways, along with an extensive assortment of commercially available stable monosaccharide isotopologs, makes glycan-based PTMs particularly well suited for isotopic recoding. Ultimately, this approach is limited by the elemental composition and metabolic origin of the PTM being studied; although a stable, three-component GlcNAc isomix can be readily prepared and incorporated by cells, a similar phosphate-based isomix is less feasible. Importantly, there is no requirement that the isotopic signature strictly mimic that of a dibrominated probe; a variety of isotopic mixtures could impart sufficient perturbation to a peptide isotopic envelope to allow for successful targeted LC-MS/MS analyses.

The approach of isotopic recoding for targeted proteomics is not limited to the genetically modified *S. cerevisiae* strain utilized in this study. Although more challenging, we believe that pathway engineering in higher eukaryotes, with the aim of gaining compositional control over specific nucleotide-sugar pools, is feasible. Although metabolic introduction of an unnatural isotopic signature was showcased here, it is important to emphasize that similar perturbations of isotopic envelopes can also be obtained via chemospecific or enzymatic labeling of specific PTMs. For example, we are investigating the possibility of *in vitro* enzymatic transfer of isomix-bearing probes to *O*-glycosylated peptides obtained from mammalian cells; this approach would obviate the need for metabolically embedding the isomix signature. We believe the concept of isotopic recoding will be a powerful technology for those interested in profiling PTMs, including but not limited to *N*-glycans, using metabolic, enzymatic, and chemical labeling methods alike, substantially bolstering confidence in the data obtained from LC-MS/MS data sets.
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